Parley-neuro

Hearing loss and tinnitus

Parley Neurotech is a neurotech and biotechnology company developing LOOT, a first-in-class therapy designed to restore hearing by repairing myelin in the brain’s auditory pathways. Its approach targets central hearing loss at its neurological root, with approximately 90% reversal reported in preclinical studies, and Phase II volunteer enrollment underway.

Visit parley-neuro.com ↗

reccy insights

Written by reccy's AI from company sites, press and funding records · updated Oct 2026

Recent highlights

Parley Neurotech has advanced its clinical development pipeline with volunteer enrollment underway for a Phase II clinical trial. The study evaluates the company's lead therapeutic candidate, LOOT, operating in collaboration with clinicians and investigators from the University of Colorado and the University of Northern Colorado. Preclinical findings released by the company indicate an approximate 90% reversal of central hearing loss pathology in animal models, establishing a strong foundation for current clinical evaluation.

Market position

Parley Neurotech operates in the specialized neurotechnology and biotechnology sectors, specifically targeting central hearing loss and auditory pathway repair. Unlike conventional hearing solutions such as hearing aids or cochlear implants—which amplify sound or mechanically stimulate the cochlea—Parley approaches hearing restoration at its neurological root by repairing myelin within the brain's auditory pathways. This therapeutic strategy positions the company distinctly among neuro-therapeutics developers, competing in the broader clinical research and neurological repair markets by addressing central auditory processing deficits rather than peripheral hearing impairment.

Growth & opportunities

The company is advancing through early-to-mid-stage clinical trials, marked by the ongoing Phase II study for its flagship LOOT therapy. Growth efforts center on translational neuroscience, moving from preclinical validation—which demonstrated substantial neurological restoration—into human clinical investigations. The trajectory is defined by clinical milestones, academic partnerships with regional research institutions, and the continued clinical validation of myelin repair mechanisms in auditory neuroscience.

Written by reccy's AI from company sites, press and funding records · updated Oct 2026

What makes Parley-neuro distinct

reccy insights

What makes Parley-neuro distinct

01Targets central hearing loss by addressing neurological damage rather than solely treating the ear.
02Developing LOOT as a first-in-class myelin repair therapy for restoring how the brain processes sound.
03Reports approximately 90% reversal in preclinical studies.
04Combines biotech startup leadership with deep academic expertise in auditory neuroscience and brainstem research.
05Conducting a Phase II clinical trial with clinicians and investigators from the University of Colorado and University of Northern Colorado.

Technology & products

LOOT
First-in-class myelin repair therapy designed to restore hearing by repairing myelin in the brain’s auditory pathways.

LOOT myelin repair therapy
Neurological treatment targeting central hearing loss and auditory brain pathways

About Parley-neuro

Products: LOOT
Focus areas: Neurotechnology, biotechnology, hearing loss, myelin repair, therapeutics, clinical research, auditory neuroscience, cognitive health
Headquarters: Aurora, CO